Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 979 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stability Clear all
Completed No phase listed Observational

Brain Perfusion and Hemodynamic Stability in Patients Undergoing Radiofrequency Ablation of Ventricular Tachycardia

NCT01695551
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Data Collection Forms
Other
Lead sponsor
Dhanunjaya Lakkireddy, MD, FACC
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 20, 2026, 2:37 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

NCT01900522
View directory record Official record
Conditions
Schizophrenia
Interventions
ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C, ITI-214 Dose D (Elderly), Placebo, ITI-214 Dose E, ITI-214 Dose F, ITI-214 Dose G, ITI-214 Dose H
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Glendale, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

NCT05181683
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
Casirivimab+Imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 20, 2026, 2:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

NCT07147231
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging, Pidnarulex, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure

NCT00323037
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
carvedilol controlled release, carvedilol immediate release
Drug
Lead sponsor
CTI-1, LLC
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
75
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 3 Interventional

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

NCT01192867
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO4917838, Antipshychotics (Standard of Care)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
27
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

NCT01275599
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders
Interventions
telaprevir, buprenorphine/naloxone
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Overland Park, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 4 Interventional Results available

Labetalol and Esmolol: Vital Signs and Post Operative Pain Management

NCT01114971
View directory record Official record
Conditions
Laparoscopic Surgery
Interventions
Fentanyl, Labetalol, Esmolol
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 1 Interventional

An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

NCT02320032
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Lauroxil
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone

NCT02675426
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
57
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 20, 2026, 2:37 AM EDT
Active, not recruiting Phase 3 Interventional

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

NCT06163326
View directory record Official record
Conditions
Vitiligo
Interventions
Ritlecitinib, Ritlecitinib 100 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
22
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 2:37 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

NCT03281304
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
CP-690,500 5 mg, CP-690,550 10 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
24
States / cities
Mobile, Alabama • San Diego, California • Bristol, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 20, 2026, 2:37 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

NCT06784947
View directory record Official record
Conditions
Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
Interventions
Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab, Atezolizumab, Bevacizumab
Procedure · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 2 Interventional

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

NCT00473525
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-00734200 10 mg QD, PF-00734200 20 mg QD, PF-00734200 5 mg QD, PF-00734200 2 mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
64
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2010 · Synced Oct 20, 2026, 2:37 AM EDT
Not listed Not applicable Interventional

Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy

NCT05266625
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BT-001, Control App
Behavioral · Other
Lead sponsor
Better Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • New Orleans, Louisiana • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 4 Interventional Results available

Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder

NCT00552760
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Lehigh Valley Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

NCT00358436
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Aclidinium bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
73
States / cities
Jasper, Alabama • Ozark, Alabama • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 3 Interventional

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01716975
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
49
States / cities
Phoenixville, Arizona • Little Rock, Arkansas • Cerritos, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 20, 2026, 2:37 AM EDT
Terminated Not applicable Interventional

Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions

NCT04271501
View directory record Official record
Conditions
Vitiligo
Interventions
Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVB), RECELL 1:5 and Ultraviolet Lamp (UVB), RECELL 1:10 and Ultraviolet Lamp (UVB), RECELL 1:20 and Ultraviolet Lamp (UVB)
Procedure · Device
Lead sponsor
Avita Medical
Industry
Eligibility
22 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 3 Interventional

Trial of Lycopene/Ateronon for Secondary Prevention of Coronary Heart Disease

NCT00939237
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Ateronon, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Oct 20, 2026, 2:37 AM EDT
Recruiting Phase 3 Interventional

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

NCT02468024
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Lung Surgery, Radiation therapy
Procedure · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
40
States / cities
La Jolla, California • Aurora, Colorado • Colorado Springs, Colorado + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 20, 2026, 2:37 AM EDT
Not listed Not applicable Interventional

Results of Patients With Glaucoma Undergoing Minimally Invasive Glaucoma Surgery in Conjunction With Cataract Surgery

NCT05624398
View directory record Official record
Conditions
Glaucoma, Open-Angle, Cataract
Interventions
Vivity IOL
Device
Lead sponsor
Vold Vision P.L.L.C
Other
Eligibility
45 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nalrexone Facilitated Discontinuation of Buprenorphine

NCT01895036
View directory record Official record
Conditions
Stable Opioid Dependence
Interventions
Naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 49 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 20, 2026, 2:37 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older

NCT02464163
View directory record Official record
Conditions
Influenza
Interventions
Panblok, rHA adjuvant
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
9
States / cities
Mobile, Alabama • DeLand, Florida • Savannah, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 20, 2026, 2:37 AM EDT